In vitro and In vivo Drug Metabolism Analysis of BPI-460372 - A Covalent TEAD1/3/4 Inhibitor
This study elucidated the metabolism of BPI-460372 and provided a basis for pharmacokinetic and toxicological species selection, human pharmacokinetics prediction, and assessment of clinical co-administration limitations and possible metabolic pathways in humans.
Authors
- Chaoying Tang (ORCID: https://orcid.org/0000-0001-5883-6941)
- Xingxing Diao (ORCID: https://orcid.org/0000-0002-6892-0861)
- Xiaofeng Xu (ORCID: https://orcid.org/0000-0001-7910-0407)
- Lan Hong (ORCID: https://orcid.org/0000-0001-7805-0663)
- Dafang Zhong
- Xiaoyun Liu
Institutions
- Chinese Academy of Sciences (CN)
- Betta Pharmaceuticals (China) (CN)
- Shanghai Institute of Materia Medica (CN)
Publication Details
- Journal
- Current Drug Metabolism
- Published
- 2024-12-01
- DOI
- https://doi.org/10.2174/0113892002351556250123105344
- Citations
- 7
- Primary Topic
- Hippo pathway signaling and YAP/TAZ
- Type
- article
- Field-Weighted Citation Impact
- 2.28
Funders
- National Natural Science Foundation of China
- Chinese Academy of Sciences
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences